Activation of AT
Akt
FOXO1
angiotensin type 2 receptor
db/db mice
gluconeogenesis
insulin receptor
renin-angiotensin system
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
05
04
2020
revised:
08
08
2020
accepted:
16
08
2020
pubmed:
28
8
2020
medline:
22
6
2021
entrez:
28
8
2020
Statut:
ppublish
Résumé
The AT Female diabetic (db/db) and non-diabetic (db/+) mice were treated for 1 month with the selective AT C21-treated db/db mice displayed improved glucose and pyruvate tolerance compared with saline-treated db/db mice. Also, C21-treated db/db mice showed reduced liver weight and decreased hepatic lipid accumulation compared with saline-treated db/db mice. Insulin signalling analysis showed increased phosphorylation of the insulin receptor, Akt and FOXO1 in the livers of C21-treated db/db mice compared with saline-treated counterparts. These findings were associated with increased adiponectin levels in plasma and adipose tissue and reduced adipocyte size in inguinal fat. The beneficial effects of AT Chronic C21 infusion exerts beneficial metabolic effects in female diabetic db/db mice, alleviating type 2 diabetes complications, through a mechanism that involves NO production.
Sections du résumé
BACKGROUND AND PURPOSE
The AT
EXPERIMENTAL APPROACH
Female diabetic (db/db) and non-diabetic (db/+) mice were treated for 1 month with the selective AT
KEY RESULTS
C21-treated db/db mice displayed improved glucose and pyruvate tolerance compared with saline-treated db/db mice. Also, C21-treated db/db mice showed reduced liver weight and decreased hepatic lipid accumulation compared with saline-treated db/db mice. Insulin signalling analysis showed increased phosphorylation of the insulin receptor, Akt and FOXO1 in the livers of C21-treated db/db mice compared with saline-treated counterparts. These findings were associated with increased adiponectin levels in plasma and adipose tissue and reduced adipocyte size in inguinal fat. The beneficial effects of AT
CONCLUSION AND IMPLICATIONS
Chronic C21 infusion exerts beneficial metabolic effects in female diabetic db/db mice, alleviating type 2 diabetes complications, through a mechanism that involves NO production.
Identifiants
pubmed: 32851652
doi: 10.1111/bph.15241
pmc: PMC7520448
doi:
Substances chimiques
Receptor, Angiotensin, Type 2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4766-4781Subventions
Organisme : NIAID NIH HHS
ID : R01 AI134714
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI132599
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30DK063491
Pays : United States
Organisme : American Heart Association
ID : 17GRNT33661206
Organisme : NHLBI NIH HHS
ID : P01 HL129941
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007770
Pays : United States
Organisme : American Heart Association
ID : 16SDG30130015
Organisme : NIDDK NIH HHS
ID : P30 DK063491
Pays : United States
Organisme : Universidad de Buenos Aires
ID : UBACYT 20020130100218BA
Organisme : NHLBI NIH HHS
ID : R01 HL142672
Pays : United States
Organisme : Fondo para la Investigación Científica y Tecnológica
ID : PICT-2014-0362
Informations de copyright
© 2020 The British Pharmacological Society.
Références
J Renin Angiotensin Aldosterone Syst. 2015 Jun;16(2):311-20
pubmed: 23736171
Am J Physiol Endocrinol Metab. 2004 Aug;287(2):E227-32
pubmed: 15082419
J Hypertens. 2009 Dec;27(12):2409-20
pubmed: 19901849
Drugs. 2016 Jan;76(1):1-12
pubmed: 26631237
PLoS One. 2012;7(11):e48387
pubmed: 23155382
J Clin Invest. 1968 Jan;47(1):153-65
pubmed: 16695937
J Biol Chem. 2002 Jul 19;277(29):25863-6
pubmed: 12032136
Am J Physiol Endocrinol Metab. 2013 Jan 15;304(2):E197-210
pubmed: 23149621
J Endocrinol. 2018 Jun;237(3):271-284
pubmed: 29643115
PLoS Biol. 2020 Jul 14;18(7):e3000410
pubmed: 32663219
Physiol Rep. 2018 Aug;6(16):e13824
pubmed: 30156060
Hypertension. 2012 Feb;59(2):409-14
pubmed: 22158645
Am J Physiol Heart Circ Physiol. 2019 May 1;316(5):H958-H970
pubmed: 30707614
J Am Soc Nephrol. 2018 Oct;29(10):2546-2561
pubmed: 30185469
Am J Physiol Regul Integr Comp Physiol. 2007 Sep;293(3):R974-80
pubmed: 17581838
Nat Protoc. 2013 Jun;8(6):1149-54
pubmed: 23702831
Biochem Biophys Res Commun. 2006 Aug 4;346(3):658-64
pubmed: 16774739
J Diabetes Res. 2018 Mar 11;2018:3086167
pubmed: 29713648
Diabetes. 2016 May;65(5):1245-54
pubmed: 26884438
Hypertension. 2014 Aug;64(2):378-83
pubmed: 24842923
Obesity (Silver Spring). 2008 Apr;16(4):770-6
pubmed: 18239590
J Clin Invest. 1997 Jul 15;100(2):264-9
pubmed: 9218502
J Invest Dermatol. 2018 Aug;138(8):1678-1682
pubmed: 30032783
Physiol Rev. 2018 Oct 1;98(4):2133-2223
pubmed: 30067154
Signal Transduct Target Ther. 2017 Jun 23;2:17022
pubmed: 29263921
Clin Sci (Lond). 2007 Aug;113(3):109-18
pubmed: 17600527
Clin Sci (Lond). 2018 Apr 6;132(7):777-790
pubmed: 29540539
Hepatology. 2010 Nov;52(5):1836-46
pubmed: 21038418
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Endocrinology. 2014 Mar;155(3):793-804
pubmed: 24302627
Pancreas. 2017 Mar;46(3):395-404
pubmed: 28099262
Biol Sex Differ. 2015 Sep 03;6:14
pubmed: 26339468
Am J Kidney Dis. 2018 Jun;71(6):884-895
pubmed: 29398179
Gastroenterology. 2003 Jul;125(1):117-25
pubmed: 12851877
Peptides. 2005 Aug;26(8):1401-9
pubmed: 16042980
Curr Pathobiol Rep. 2015 Dec;3(4):253-261
pubmed: 26726307
Am J Hypertens. 1995 Apr;8(4 Pt 1):353-7
pubmed: 7619347
J Clin Invest. 2006 Jul;116(7):1793-801
pubmed: 16823477
Br J Pharmacol. 2020 Oct;177(20):4766-4781
pubmed: 32851652
Endocrinology. 2018 Feb 1;159(2):685-695
pubmed: 29186390
Cardiovasc Res. 2004 Jun 1;62(3):587-93
pubmed: 15158151
Br J Pharmacol. 2020 Aug;177(16):3611-3616
pubmed: 32662875
Hypertension. 2004 May;43(5):1003-10
pubmed: 15037562
Nature. 2006 Dec 14;444(7121):840-6
pubmed: 17167471
Curr Opin Nephrol Hypertens. 2017 Mar;26(2):91-96
pubmed: 27906747
Br J Pharmacol. 2018 Feb;175(3):407-411
pubmed: 29350411
Nat Med. 2001 Aug;7(8):947-53
pubmed: 11479628
Metabolism. 2015 Jul;64(7):814-25
pubmed: 25869303
Curr Opin Pharmacol. 2011 Apr;11(2):187-92
pubmed: 21167778
Physiol Rev. 2018 Jul 1;98(3):1627-1738
pubmed: 29873596
Mol Cell Biochem. 2019 Nov;461(1-2):195-204
pubmed: 31414336
Biochem Soc Trans. 2006 Nov;34(Pt 5):798-801
pubmed: 17052201
Free Radic Biol Med. 2014 Aug;73:383-99
pubmed: 24878261
Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141
pubmed: 31710717
Am J Physiol Endocrinol Metab. 2013 Nov 15;305(10):E1281-91
pubmed: 24085035